News Column

Lion Biotechnologies’ CEO Manish Singh, Ph.D., to Chair Opening Session at Phacilitate’s Immunotherapy Forum on January 27

January 24, 2014



LOS ANGELES--(BUSINESS WIRE)-- Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive Officer Manish Singh, Ph.D., will preside over the introductory session of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014. Titled “Overviewing key trends in immunotherapy R&D investment, collaboration and pipeline strategies,” the session will include presentations by executives from biotechnology and pharmaceutical companies, and a panel discussion with life science industry and venture capital executives.

In addition, Lion Biotechnologies’ Vice President, Product Development and Manufacturing, James G. Bender, Ph.D., will be a panelist in a key breakfast briefing titled “Development by design – a model for managing comparability risks and optimizing process development for Cell Therapy and Immunotherapy processes,” on Wednesday, January 29.

The Immunotherapy Forum is being held January 27-29 at The Grand Hyatt Hotel in Washington D.C., and is part of Phacilitate’s Washington Bioleaders 2014 Conference.

“We are pleased to have an important role in this year’s Immunotherapy Forum, which will have an audience of 500-600 executives from the pharma and biotech industries, as well as key external stakeholders, including the world's regulators, public and private sector investors, NGOs, payers and analysts,” said Dr. Singh. “The conference provides an excellent opportunity to network with leaders from industry, government and the investment community, and discuss recent progress in our T-cell development program.”

About Lion Biotechnologies

Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit http://www.lionbio.com.





INVESTOR CONTACT:

LHA

Don Markley

Senior Vice President

310-691-7100

dmarkley@lhai.com


Source: Lion Biotechnologies, Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Business Wire


Story Tools